skip to Main Content

Pegilodecakin Plus FOLFOX in Advanced Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Clinical data on an investigational immuno-oncology drug pegilodecakin (PEGylated human interleukin-10, also known as AM0010) was presented by Hecht et al at the ESMO 19th World Congress on Gastrointestinal Cancer in Barcelona, Spain (Abstract O-004).

Pegilodecakin is being evaluated in an ongoing phase I/Ib clinical trial that has enrolled 352 advanced cancer patients and in a phase III clinical trial that is enrolling patients with advanced pancreatic cancer.

“In an ongoing phase I/Ib clinical trial, pegilodecakin in combination with FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy has demonstrated extremely promising efficacy and safety data to date in patients with advanced pancreatic cancer,” said J. Randolph Hecht, MD, Professor of Clinical Medicine, David Geffen School of Medicine at the University of California Los Angeles, and an investigator for the phase III clinical trial. “The median follow-up on this study is 14.2 months (range, 6.8–18.9 months) and 10 of 21 patients (47%) are still alive after more than 1 year.” Read more . . .

Back To Top